Breaking News

**BREAKING: Opus Genetics Inc. Reports Q4 2025 Results**

Apyx Medical narrows Q4 loss to $0.06 per share as revenue surges 34.8% year-over-year to $19.2 million, with fiscal 2026…

**Cullinan Therapeutics Inc Reports Q4 2025 Results**

**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss**

Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.

Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.

**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**

Priority Technology Holdings posted Q4 adjusted EPS of $0.27, up 621% year-over-year, with revenue climbing 8.8% to $247.1 million.

Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential improvement.

Septerna reports Q4 loss of $0.24/share, wider than expected, as revenue climbs to $24.1M from minimal levels earlier in fiscal…